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ABSTRACT
Background and aim Colorectal cancer (CRC) is
a multifactorial disease with both environmental and
genetic factors contributing to its development. The
incidence of CRC is increasing year by year in Japan.
Patients with CRC in advanced stages have a poor
prognosis, but detection of CRC at earlier stages can
improve clinical outcome. Therefore, identiﬁcation of
epidemiologial factors that inﬂuence development of CRC
would facilitate the prevention or early detection of
disease.
Methods To identify loci associated with CRC risk, we
performed a genome-wide association study (GWAS) for
CRC and sub-analyses by tumour location using 1583
Japanese CRC cases and 1898 controls. Subsequently,
we conducted replication analyses using a total of 4809
CRC cases and 2973 controls including 225 Korean
subjects with distal colon cancer and 377 controls.
Results We identiﬁed a novel locus on 6q26-q27 region
(rs7758229 in SLC22A3,p ¼7.92310
 9, OR of 1.28)
that was signiﬁcantly associated with distal colon
cancer. We also replicated the association between CRC
and SNPs on 8q24 (rs6983267 and rs7837328,
p¼1.51310
 8 and 7.44310
 8, ORs of 1.18 and 1.17,
respectively). Moreover, we found cumulative effects of
three genetic factors (rs7758229, rs6983267, and
rs4939827 in SMAD7) and one environmental factor
(alcohol drinking) which appear to increase CRC risk
approximately twofold.
Conclusions We found a novel susceptible locus in
SLC22A3 that contributes to the risk of distal colon
cancer in an Asian population. These ﬁndings would
further extend our understanding of the role of common
genetic variants in the aetiology of CRC.
INTRODUCTION
Colorectal cancer (CRC) is the third most common
cancer and the fourth leading cause of cancer death
worldwide. The recent development of novel drugs
and therapeutics has remarkably improved overall
survival, and the 5-year survival rate is around 90%
for patients who are diagnosed at stage I.
1
However, the prognosis of patients with CRC in an
advanced stage is still disappointing. Hence, iden-
tiﬁcation of epidemiologicalfactors that inﬂuence
development of the disease would facilitate its
prevention or early detection and subsequently
provide better prognosis.
Family history is acknowledged to be one of the
strong risk factors, and an approximately twofold
increased risk for CRC was observed among
patients who have a ﬁrst-degree relative with
CRC.
2 Thus, nearly 15% of patients with CRC
have a positive family history of disease.
3e5
Although inherited susceptibility was thought to
account for w35% of all CRC,
6 high-risk germline
mutations in APC, DNA mismatch repair genes,
MUTYH, SMAD4, BMPR1A, and LKB1 account for
<6% of all cases.
7 Therefore, the remaining heri-
table CRC risk (approximately 30%) would be
caused by the combination of common variants
with modest effects.
Recent genome-wide association studies
(GWASs) among European populations have iden-
tiﬁed a subset of CRC susceptibility loci in 8q24,
8 9
8q23.3 (EIF3H),
10 10p14,
10 11q23,
11 15q13,
12 18q21
(SMAD7),
11 13 14q22.2 (BMP4),
14 16q22.1
(CDH1),
14 19q13.1(RHPN2),
14 and 20p12.3.
14
However, no GWAS for CRC in an Asian
< Additional ﬁgures and tables
are published online only. To
view these ﬁles please visit the
journal online (http://gut.bmj.
com).
1Laboratory of Molecular
Medicine, Human Genome
Center, Institute of Medical
Science, The University of
Tokyo, Tokyo, Japan
2Laboratory of Functional
Genomics, Human Genome
Center, Institute of Medical
Science, The University of
Tokyo, Tokyo, Japan
3Laboratory of Cell Biology,
Cancer Research Institute, Seoul
National University College of
Medicine, Seoul, Korea
4Laboratory for Genotyping
Development, Center for
Genomic Medicine, The Institute
of Physical and Chemical
Research (RIKEN), Kanagawa,
Japan
5Laboratory for Medical
Informatics, Center for Genomic
Medicine, The Institute of
Physical and Chemical Research
(RIKEN), Kanagawa, Japan
6Laboratory for Statistical
Analysis, Center for Genomic
Medicine, The Institute of
Physical and Chemical Research
(RIKEN), Kanagawa, Japan
7Laboratory for International
Alliance, Center for Genomic
Medicine, The Institute of
Physical and Chemical Research
(RIKEN), Kanagawa, Japan
Correspondence to
Dr Koichi Matsuda, Laboratory
of Molecular Medicine, Human
Genome Center, Institute of
Medical Science, The University
of Tokyo, 4-6-1, Shirokanedai,
Minato-ku, Tokyo 108-8639,
Japan;
koichima@ims.u-tokyo.ac.jp
Revised 1 November 2010
Accepted 8 November 2010
Published Online First
17 January 2011
This paper is freely available
online under the BMJ Journals
unlocked scheme, see http://
gut.bmj.com/site/about/
unlocked.xhtml
Signiﬁcance of this study
What is already known about this subject?
< Inherited susceptibility was thought to account
for w35% of all colorectal cancer (CRC).
< Genome-wide association studies (GWASs)
among European populations have identiﬁed
a subset of CRC susceptibility loci.
< Different genetic factors may contribute to the
pathogenesis of distal colon cancer and prox-
imal colon cancer.
What are the new ﬁndings?
< A GWAS for CRC was conducted for the ﬁrst
time in an Asian population and identiﬁed
a novel susceptible locus in SLC22A3 that was
signiﬁcantly associated with distal colon cancer.
< Genetic and environmental factors play a crucial
role in the development of CRC in this Asian
population.
< Interesting racial diversity between Asian and
Caucasian populations in the pathogenesis of
colorectal cancer was suggested.
How might it impact on clinical practice in the
foreseeable future?
< Our ﬁndings would contribute to the under-
standing of the cumulative role of genetic and
environmental factors in colorectal carcinogen-
esis in the Asian population and also establish
personalised medical treatment.
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Colonpopulation has been performed. To explore the variants that
predispose to the disease in an Asian population, we conducted
a GWAS for CRC and sub-analyses by tumour location.
METHODS
Study population
In this study, we used a total of 6167 CRC cases and 4494
control subjects from a Japanese population. CRC patients were
categorised into two main groups (colon and rectal cancers)
according to the tumour location. For the colon cancer, we
further categorised into proximal colon (caecum, ascending
colon, and transverse colon) and distal colon (descending colon,
and sigmoid colon) cancers. Characteristics of each cohort are
shown in table 1. Case samples of the Japanese population were
obtained from BioBank Japan (http://biobankjp.org/).
15 Control
DNA samples in the screening stage were obtained from healthy
volunteers (n¼904, 74.4% males, mean age at diagnosis¼52.5
years, SD614.3) as well as from BioBank Japan (n¼994, keloi-
dosis, chronic hepatitis B, pulmonary tuberculosis, and drug
rash). To increase the power to detect genetic factors related
with CRC, we used cases with higher hereditary predisposition
in our screening stage. CRC cases who developed the disease at
a younger age (#60 years old) or had at least one ﬁrst-degree
relative with a history of CRC were enriched in our screening
stage cohort (62.80% and 35.5%, respectively) compared to the
ﬁrst replication (21.17% and 3.62%, respectively) and the second
replication cohorts (21.62% and 8.28%) (supplementary table 1).
Genotyping results of 2596 individuals that were registered in
BioBank Japan were used as the controls for the ﬁrst (ischaemic
stroke and myocardial infarction) and the second (peripheral
artery disease and arrhythmia) replication analyses. We excluded
the subjects with cancers or diabetes from control groups.
Patients with inﬂammatory bowel diseases (ulcerative colitis
and Crohn’s disease) were not included as either cases or
controls. Cases and controls (healthy volunteers) for the third
replication (n¼225 and 377, respectively) were collected at
Cancer Research Institute, Seoul National University College of
Medicine, Korea. All the participants provided written informed
consent.
SNP genotyping and quality control
Platforms used in each stage are shown in table 1. Analyses using
Illumina Beadchip (Illumina, San Diego, California, USA) were
conducted at the Center for Genomic Medicine, The Institute of
Physical and Chemical Research. In the ﬁrst and the second
replication analyses, genotyping of case samples was conducted
by the multiplex polymerase chain reaction-based Invader assay
(Third Wave Technologies, Madison, Wisconsin, USA).
16 Korean
samples in the third replication analysis were genotyped using
the Taqman assay (Applied Biosystems, San Francisco, Cali-
fornia, USA). To evaluate the quality of each genotyping
methods, we analysed rs7758229 in 96 CRC cases. Conse-
quently, we observed more than 99% concordance between the
result from direct sequencing and those from three genotyping
systems (invader, Taqman, and Illumina Human610-Quad
BeadChip). These ﬁndings indicated that different genotyping
methods are not likely to cause the inﬂation of association in our
study.
In the screening stage, we genotyped 1595 CRC cases and
1903 control subjects. These samples were genotyped using the
Illumina Human610-QuadBeadChip in cases and the Illumina
HumanHap550v3 BeadChip in controls. In fact, genotype
concordance between these two BeadChips was 99.99% among
182 duplicate samples, indicating a low possibility of genotype
error. The samples with a call rate of < 0.98 were excluded from
our analysis (12 cases and ﬁve controls). Then we applied SNP
quality control as follows: call rate $0.99 in cases and controls,
HardyeWeinberg p$1310
 7 in controls. Finally, 496531
common SNPs between Human610-Quad Beadchip and
HumanHap550v3 Genotyping BeadChip on autosomal chro-
mosomes passed the quality control criteria. We selected 391749
SNPs with minor allele frequency (MAF) of $0.05 in either case
or control samples for further analyses, considering statistical
power in the replication analyses.
Statistical analysis
In the screening stage, the associations between each SNP and
CRC were assessed using the CochraneArmitage trend test.
Thirty-six SNPs that exhibited false discovery rate Q value #0.2
(p#2.5310
 5) were further analysed using an independent
cohort consisting of 3099 CRC cases and 1777 controls. Sub-
analyses by tumour location were also performed applying the
same criteria (p#2.5310
 5). The signiﬁcance thresholds were
set to be 0.05 in the ﬁrst, second and third replication study, and
1.27310
 7 (0.05/391749) in the meta-analysis. When we take
account of the sub-group analyses for multiple testing correc-
tion, the genome-wide signiﬁcance threshold is 2.54310
 8 (0.05/
(39174935)). The statistical powers to detect a variant with OR
of 1.3 and MAF of 0.2 were estimated to be 62.6%, 99.9% and
94.2% (screening stage, ﬁrst and second replication) for CRC,
and 19.1%, 95.8%, and 77.2% for distal colon cancer, respec-
tively. ORs and CIs were calculated using the major allele as
a reference. Since alcohol intake of more than two standard
drinks (28 g of pure alcohol per day) was shown to increase the
risk of CRC,
17 we classiﬁed the subjects into three categories:
non-drinkers (0e1 g/day of alcohol), light drinkers (1e28 g/day
of alcohol), or heavy drinkers ($28 g/day of alcohol). Multiple
logistic regression analysis was used to assess the contributions
of the confounding factors with the R program (version 2.8.1).
Age and gender were designated as regulatory factors, and the
following explanatory variables were included in the analysis:
alcohol consumption status (0¼non-drinker, 1¼light drinker,
2¼heavy drinker), tobacco smoking (0¼never smoker,
1¼smoker) and rs7758229 genotype (0¼GG, 1¼TG, 2¼TT).
Imputation analysis
To investigate the region including SNP rs7758229, imputation
of ungenotyped SNPs was conducted by MACH v1.0 (see URLs)
using ﬁrst screening GWAS dataset with reference to the release
27 JPT (Japanese in Tokyo, Japan) from the HapMap Project
website. Imputed SNPs with an Rsq value <0.3 were excluded.
We also genotyped two exonic SNPs (rs668871 and rs2292334) in
48 cases and 48 controls by direct sequencing and found that the
results from imputation analysis were completely consistent
with those from sequence analysis.
SNP discovery
We performed re-sequencing of the promoter region and all
exons of the SLC22A3 gene using genomic DNA from 48 indi-
viduals with distal colon cancer and 48 healthy controls. Primers
used for ampliﬁcation and sequence analyses were indicated in
the supplementary table 9.
RESULTS
To identify common variants that inﬂuence CRC risk, we
genotyped 1583 Japanese individuals with CRC and 1898
800 Gut 2011;60:799e805. doi:10.1136/gut.2010.215947
Coloncontrol individuals (supplementary ﬁgure 1A). To overcome the
relatively low statistical power in the screening stage, patients
under 60 years old who developed cancer or who had a positive
family history were preferentially enrolled in the screening stage,
as mentioned in the methods section. We also performed sub-
analysis by tumour location (colon, proximal colon, distal colon
and rectal cancer) to explore common variants that predispose to
some subsets of CRC (supplementary ﬁgure 1BeE). Application
of the CochraneArmitage trend test to all the tested SNPs
indicated that the genomic inﬂation factor l was 1.05, 1.04, 1.02,
1.03 and 1.02 for the colorectal, colon, proximal colon, distal
colon and rectal cancers, respectively (supplementary ﬁgure
2AeE). For CRC, the inﬂation factor l was 1.05 in our study.
Since the inﬂation factor is highly dependent on sample size,
18 19
we calculated it by using 1000 cases and 1000 controls. As
a result, the inﬂation factor becomes as small as 1.03, implying
a low possibility of false positive associations due to population
stratiﬁcation.
SNPs with a false discovery rate Q value #0.2 (p#2.5310
 5)
in the screening stage were considered as candidates. Thus, 36
SNPs for CRC, 27 SNPs for colon cancer, 20 SNPs for proximal
colon cancer, 18 SNPs for distal colon cancer, and nine SNPs for
rectal cancer were selected for further analyses (supplementary
tables 2e6). In the ﬁrst replication study, we genotyped these
candidate SNPs using independent cohorts consisting of up to
3099 cases and 1777 controls (table 1). Two SNPs for CRC
(table 2) and one SNP for distal colon cancer (table 3) exhibited
a p value lower than 0.05. Then we analysed these SNPs in 1485
CRC cases, 489 distal colon cancer cases, and 819 controls,
respectively. As a result, all three SNPs showed a p value lower
than 0.05 in the second replication study. Consequently, we
identiﬁed a signiﬁcant association between CRC and SNPs on
8q24 (rs6983267 and rs7837328, p¼1.51310
 8 and 7.44310
 8,
respectively; table 2), which have been reported to be associated
with CRC in studies of Caucasian subjects.
8 In addition, we
identiﬁed a novel locus (rs7758229 on 6q26-q27) that was
signiﬁcantly associated with distal colon cancer. Meta-analysis
of all stages showed a ManteleHaenszel p value of 1.07310
 8
and OR of 1.29 (table 3). Since rs7758229 did not associate with
any disease that was used in the control group in our study
(supplementary ﬁgure 4), the case-mix cohort is not likely to
affect the association between rs7758229 and distal colon cancer.
For this novel locus, we conducted a replication study using
225 Korean subjects with distal colon cancer and 377 controls.
Although the association was not signiﬁcant, we observed
a similar trend in the samples from the Korean subjects (p¼0.286
with OR of 1.16) and ManteleHaenszel p value for indepen-
dence had improved from 1.07310
 8 to 7.92310
 9 (OR of 1.28,
Pheterogeneity¼0.20; table 3) when we conducted a meta-analysis
of the Japanese and Korean study with a ﬁxed-effects model.
Table 1 Characteristics of study populations
Cohort Source Platform
Number of
samples Male
Age
(mean±SD)
Drinking status
Nondrinker
Light
drinker
Heavy
drinker
Screening stage
Case
Colorectal cancer BioBank Japan Illumina HumanHap 610k 1583 60.83% 58.37610.91 53.38% 25.65% 20.97%
Colon cancer BioBank Japan Illumina HumanHap 610k 1025 58.44% 59.33611.20 55.51% 23.90% 20.59%
Proximal colon cancer BioBank Japan Illumina HumanHap 610k 410 54.15% 60.79611.75 60.24% 22.44% 17.32%
Distal colon cancer BioBank Japan Illumina HumanHap 610k 579 60.97% 58.07610.49 52.68% 24.70% 22.62%
Rectal cancer BioBank Japan Illumina HumanHap 610k 497 63.98% 55.7869.82 50.10% 28.37% 21.53%
Control Midosuji Rotary
Club and BioBank Japan
Illumina HumanHap 550k 1898 63.78% 52.49614.38 52.50% 34.37% 13.13%
First replication
Case
Colorectal cancer BioBank Japan Invader assay 3099 63.52% 66.7768.76 59.57% 24.07% 16.36%
Colon cancer BioBank Japan Invader assay 1618 62.16% 67.6468.55 60.19% 24.42% 15.39%
Proximal colon cancer BioBank Japan Invader assay 737 58.61% 68.9068.72 63.31% 23.03% 13.66%
Distal colon cancer BioBank Japan Invader assay 848 64.62% 66.6268.25 57.06% 25.84% 17.10%
Rectal cancer BioBank Japan Invader assay 869 66.55% 65.8568.28 57.29% 25.79% 16.92%
Control BioBank Japan Illumina HumanHap 610k 1777 76.14% 60.56610.33 57.45% 27.35% 15.20%
Second replication
Case
Colorectal cancer BioBank Japan Invader assay 1485 64.75% 67.3969.92 61.62% 20.52% 17.86%
Colon cancer BioBank Japan Invader assay 854 63.58% 68.1869.63 62.11% 20.91% 16.98%
Proximal colon cancer BioBank Japan Invader assay 355 58.31% 69.0169.95 66.47% 19.20% 14.33%
Distal colon cancer BioBank Japan Invader assay 489 66.67% 67.5269.35 58.59% 22.57% 18.84%
Rectal cancer BioBank Japan Invader assay 402 67.00% 66.4669.62 62.56% 18.85% 18.59%
Control BioBank Japan Illumina HumanHap 610k 819 74.11% 68.58611.01 59.95% 21.86% 18.19%
Third replication
Case
Distal colon cancer Seoul National Univ TaqMan Genotyping System 225 65.33% 58.80612.90
Control Seoul National Univ TaqMan Genotyping System 377 66.84% 56.73610.90
CRC patients were categorised into two main groups (colon and rectal cancers) according to the tumour location. For the colon cancer, we further categorised into proximal colon (caecum,
ascending colon, and transverse colon) and distal colon (descending colon, and sigmoid colon) cancers. The control samples from BioBank Japan consisted of the individuals with diseases
other than cancer. Third replication samples derived from Korea consisted of distal colon cancer patients and healthy controls.
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ColonInterestingly, rs7758229 exhibited a much stronger effect on the
risk of distal colon cancer among younger populations and the
patients with a family history of the disease (supplementary
ﬁgure 5). Taken together, this association appears to be true.
SNP rs7758229 is located within an intron 5 of SLC22A3 (the
solute carrier family 22, member 3), one of the organic cation
transporter genes. Organic cation transporters are critical for the
elimination of some drugs and environmental toxins. This SNP
is located within a recombination hot spot between two linkage
disequilibrium blocks spanning an approximately 350-kb region
on chromosome 6q26-q27 (ﬁgure 1). To further investigate this
candidate region, we conducted imputation analysis using
a screening stage genome-wide dataset. As a result, many SNPs
within the SLC22A3 gene locus indicated strong association
(supplementary ﬁgure 3), suggesting a possible role of SLC22A3
in the pathogenesis of distal colon cancer. To identify the caus-
ative variant(s) that might alter the function or expression level
of SLC22A3, all exons and the promoter region of SLC22A3 gene
were re-sequenced using genomic DNA from 48 cases and 48
healthy controls. As a result, we identiﬁed three novel SNPs
consisting of one non-synonymous SNP (novel v1, Serine106-
Glycine) in exon 1 and two synonymous SNPs (novel v2, novel
v3) in exon 3 and 8 (supplementary table 7). In addition to these
three novel SNPs, 19 tag SNPs were genotyped using 1916 distal
colon cancer cases (screening stage, the ﬁrst and the second
replication studies) and 1818 controls (screening stage).
Although three SNPs in intron 1 (rs884742) and intron 5
(rs3123636 and rs3106164) exhibited suggestive associations
with distal colon cancer; no variants indicated stronger associ-
ation than marker SNP rs7758229 (supplementary table 7).
The cumulative epidemiological evidence revealed that various
environmental factors such as alcohol drinking, tobacco
smoking, physical activity and diet would affect the risk of
CRC.
17 20 Since histories of alcohol drinking and tobacco
smoking were available for most of case and control subjects, we
performed multiple logistic regression analysis using alcohol
drinking and smoking as covariates. As shown in table 4,
rs7758229 and alcohol consumption are independent risk factors
for distal colon cancer (p¼5.61310
 9, OR of 1.31 and
p¼1.53310
 6, OR of 1.21, respectively) after adjustment of age
and sex.
To assess the impact of SNP rs7758229 on CRC predisposi-
tion, we genotyped this variant using all CRC cases. As a result,
this variant indicated suggestive association with colon cancer
(p¼7.40310
 7 with OR of 1.21; supplementary table 10) and
CRC (p¼1.31310
 5 with OR of 1.16; supplementary table 11),
respectively.
We also analysed CRC loci that were reported in Caucasian
GWASs using our screening stage cohort. Among the nine SNPs
evaluated, SNP rs6983267 (p¼1.08310
 5, OR of 1.25) and
rs4939827 (p¼9.54310
 5, OR of 1.25; SMAD7) indicated strong
association. In addition, SNP rs10795668 showed moderate
association (p¼2.47310
 2, OR of 0.90), while the other six
SNPs did not associate with CRC. Similar results were observed
for all the nine SNPs when we used only 904 healthy subjects as
control, and MAFs of all the nine SNPs in screening stage control
samples were almost the same as those in the healthy control
samples (supplementary table 8). These results suggest that
these three variants are common CRC susceptible loci between
Caucasian and Asian populations.
Then we assessed the combined impact of three genetic
factors (rs6983267;8q24, rs4939827;SMAD7, and rs7758229;
SLC22A3) and alcohol consumption on the risk of CRC. We
assigned a score of 0, 1 or 2 for non-, light, and heavy drinkers, as
well as a score of 1 for each risk allele of each SNP. Since patients
with a score of 2 were most common in control subjects
(30.6%), we used these subjects as a reference (ﬁgure 2A). As
a result, individuals with a score of 5 or above have an
Table 2 The combined results of screening stage, ﬁrst replication and second replication analyses for colorectal cancer
SNP Allele (1/2) Chr/gene Stage
Case Control
OR (95% CI)y p Value* 11 12 22 MAF 11 12 22 MAF
rs6983267 (T/G) 8q24/Not in gene Screening stage 593 757 233 38.63 826 869 203 33.59 1.25 (1.13 to 1.37) 1.08E-05
First replication 1214 1476 408 36.99 764 782 231 35.00 1.09 (1.01 to 1.19) 4.91E-02
Second replication 540 701 239 39.83 347 378 94 34.55 1.26 (1.11 to 1.42) 4.24E-04
Combination 2347 2934 880 38.09 1937 2029 528 34.32 1.18 (1.11 to 1.25) 1.51E-08
rs7837328 (A/G) 8q24/Not in gene Screening stage 209 750 624 36.89 189 842 867 32.14 1.23 (1.12 to 1.36) 2.78E-05
First replication 366 1448 1283 35.20 209 760 808 33.15 1.10 (1.00 to 1.20) 4.01E-02
Second replication 215 688 580 37.69 86 368 365 32.97 1.23 (1.08 to 1.40) 1.42E-03
Combination 790 2886 2487 36.23 484 1970 2040 32.69 1.17 (1.10 to 1.24) 7.44E-08
*p Values derived from CochraneArmitage trend tests.
yOR of minor allele from 232 allele frequency table.
MAF, minor allele frequency
Table 3 Results of replication studies and meta-analyses for distal colon cancer
SNP Allele (1/2) Gene Stage
Case Control
OR (95% CI)* p Valuey p Heterogeneityz 11 12 22 11 12 22
rs7758229 (T/G) SLC22A3 Screening stage 53 232 292 97 641 1156 1.46 (1.26 to 1.70) 5.58E-07
First replication 62 313 472 96 603 1077 1.21 (1.05 to 1.38) 7.13E-03
Second replication 30 191 268 33 295 490 1.22 (1.01 to 1.47) 3.22E-02
Meta-analysis (Japanese)x 1.29 (1.18 to 1.41) 1.07E-08 0.13
Third replication 9 85 130 15 124 238 1.16 (0.88 to 1.54) 2.86E-01
Meta-analysis (Asian)x 1.28 (1.18 to 1.39) 7.92E-09 0.20
*OR of minor allele from 232 allele frequency table.
yp Values derived from CochraneArmitage trend tests.
zResults of BresloweDay tests.
xMeta-analyses of Japanese and Asian populations, respectively. OR and p value for independence test were calculated by the ManteleHaenzel method.
802 Gut 2011;60:799e805. doi:10.1136/gut.2010.215947
Colonapproximately twofold higher risk of developing CRC compared
with individuals with a scores of 2 (ﬁgure 2B). These results
indicate that genetic and environmental factors play a crucial
role in the development of CRC.
DISCUSSION
CRC that arises proximal or distal to the splenic ﬂexure exhibits
differences in incidence according to age, gender and ethnicity.
For example, distal colon cancers predominantly occur in white
males, while proximal colon cancers are frequent among older
AfricaneAmericans females.
21 22 The hereditary familial forms
of CRC, familial adenomatous polyposis (FAP) and hereditary
non-polyposis CRC (HNPCC) also exhibit markedly different
clinical features.
23 Nearly 100% of individuals with FAP will
develop CRC in the distal colon.
24 In contrast, approximately
70% of large bowel tumours in individuals with HNPCC arise in
the proximal colon.
25 In addition, mutations in TP53 are
approximately 1.5- to 3-fold more frequent in distal colon cancer
compare with proximal colon cancer.
26 Recently, the incidence
of colon cancer in Japan has been increasing.
27 In addition, CRC
occurs more frequently in the proximal colon and less frequently
in the rectum among the JapaneseeAmerican population in
Hawaii compared to native Japanese in Japan.
28 These facts
suggest that different genetic and environmental factors
contribute to the pathogenesis of rectal, distal and proximal
colon cancer, respectively.
To date, many studies have shown the associations between
various polymorphisms and the risk of CRC, but few have
analysed cancer risk by tumour location. In this study, we have
identiﬁed a novel locus on 6q26-q27, tagged by rs7758229 in
SLC22A3 which was signiﬁcantly associated with distal colon
cancer in Asians. The 6q26-q27 region contains four genes,
including SLC22A2, SLC22A3, LPAL2 and LPA. Imputation
analysis of 6q26-q27 region indicated that SNPs around SLC22A3
revealed strong associations. Interestingly, SNP rs9364554 in
intron 5 of SLC22A3 was shown to associate with prostate
cancer in Caucasian populations.
29 Thus SLC22A3 is likely to be
associated with multiple cancers.
SLC22A3 is a member of the organic cation transporter family
that is highly expressed in liver, kidney, intestine and brain.
30
Figure 1 Caseecontrol association results, genomic structure, and linkage disequilibrium map of chromosomal region of 6q26-q27. The top panel
shows single-marker association results calculated by CochraneArmitage trend tests. Results from the screening stage and combined analysis
(screening stage, ﬁrst and second replication studies) are indicated by black and red dots, respectively. The bottom panel shows the pairwise linkage
disequilibrium for SNPs in HapMap JPT. The red line indicates the signiﬁcance threshold after Bonferroni’s correction for multiple testing
(p¼1.27310
 7).
Table 4 Logistic regression analysis
OR (95% CI) p Value*
rs7758229 1.31 (1.20 to 1.43) 5.61E-09y
Alcohol consumption 1.21 (1.12 to 1.31) 1.53E-06y
Smoking 0.92 (0.80 to 1.05) 2.10E-01
ORs were adjusted for age and sex.
*p Values derived from the Wald test.
yThe p value of less than 0.05 was considered statistically signiﬁcant.
Gut 2011;60:799e805. doi:10.1136/gut.2010.215947 803
ColonThis family members play a critical role for the transport of
cationic drugs, toxins, and endogenous metabolites.
31 SLC22A3
is expressed in many cancer cell lines, such as colorectal and
kidney cancers, and its expression level is correlated with the
sensitivity to chemotherapeutic agents.
32 33 Since several toxins
or endogenous metabolites such as lipopolysaccharide
34 and
linoleic acid metabolite
35 were shown to induce tumour
formation, SLC22A3 might be involved in colorectal tumori-
genesis through the clearance of some carcinogen.
Numerous studies have indicated that alcohol drinking could
be positively associated with CRC risk. In addition, alcohol
intake increases the risk of distal colon cancer
17 and/or rectal
cancer
36 37 than proximal colon cancer. Furthermore, the effect
of alcohol drinking is stronger among Asian populations because
of their relatively high prevalence of a slow-metabolising alde-
hyde dehydrogenase variant.
15 38 Similarly, our study validated
that alcohol consumption was strongly associated with distal
colon cancer in the Japanese population.
In summary, we have identiﬁed a novel susceptible locus in
SLC22A3 that contributes to a risk of distal colon cancer. The
incidence of CRC was increasing with the Westernisation of
lifestyle and dietary habit in Japan.
39 However, only three of
nine CRC susceptibility loci from studies of Caucasians
exhibited a p value of less than 0.05 in our study. These results
suggest an interesting racial diversity between Asians and
Caucasians in the colorectal pathogenesis. Although further
functional studies are essential, our ﬁndings extend the under-
standing of the cumulative role of genetic and environmental
factors in the colorectal carcinogenesis in the Asian population.
URLs for items used in the imputation analysis
R statistical environment, http://cran.r-project.org/; PLINK,
http://pngu.mgh.harvard.edu/wpurcell/plink/; MACH 1.0,
http://www.sph.umich.edu/csg/abecasis/mach/.
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Editor’s quiz: GI snapshot
ANSWERS
From the questions on page 758
T2-weighted MRI of the brain demonstrates hazy, symmetrical,
bilateral, high signal involving the white matter of the frontal
and parietal lobes. This unusual combination of a diffuse
leucoencephalopathy with severe gastrointestinal dysmotility,
1 2
cachexia, external ophthalmoplegia and peripheral neuropathy is
highly suggestive of the autosomal recessive disorder, mito-
chondrial neurogastrointestinal encephalomyopathy (MNGIE).
This rare disease arises from loss-of-function mutations in the
nuclear thymidine phosphorylase (TP) gene, which leads to
secondary depletion and deletions in mitochondrial DNA.
3
Gastrointestinal disturbance pre-dates neurological symptoms in
>50% of patients and leucoencephalopathy seems to be evident
in all patients with conﬁrmed TP deﬁciency.
4
Diagnosis was conﬁrmed by demonstrating a marked increase
in the normally undetectable purines, thymidine and deoxyur-
idine, in both the plasma (13 and 17 mmol/l, respectively) and
urine (0.2 and 0.3 mmol/l, respectively) and very low white cell
TP activity (2 nmol/h/mg protein (normal range: 336e1341)).
Sequencing of the TP gene identiﬁed compound heterozygosity
for two novel mutations (TYMP:c.1167T/C and TYMP:
c.1198_1203delGTGCTG). These mutations would lead to an
amino acid substitution (p.V389G) and amino acid deletions
(p.V400_L401del), respectively, in TP. His parents and younger
sibling are phenotypically normal.
Management of MNGIE includes long-term parenteral nutri-
tion and supportive care for the peripheral neuropathy. Though
coenzyme Q10 is sometimes prescribed for mitochondrial
disorders there is no clear supporting evidence for its routine use
in MNGIE.
5 Novel treatments being investigated for MNGIE
include dialysis,
6 allogenic stem cell transplantation
7 and
administration of carrier erythrocyte-entrapped TP.
8
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